Par Pharmaceutical
Companies, Inc. (NYSE: PRX) announced that it has completed the
acquisition of privately-held Edict Pharmaceuticals Private Limited, an
India-based developer and manufacturer of generic pharmaceuticals.
Edict is a Chennai, India-based developer
and manufacturer of solid oral dosage generic pharmaceuticals with a
highly-skilled research and development team and strong product pipeline
focused on niche first-to-file, first-to-market products. Edict
currently has 11 ANDAs filed with the U.S. FDA.
About Par Pharmaceutical Companies, Inc.Par Pharmaceutical
Companies, Inc. is a U.S.-based specialty pharmaceutical company.
Through its wholly-owned subsidiary's two operating divisions, Par
Pharmaceutical and Strativa Pharmaceuticals, it develops, manufactures
and markets high barrier-to-entry generic drugs and niche, innovative
proprietary pharmaceuticals. For press release and other company
information, visit www.parpharm.com.
No comments:
Post a Comment